Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16474674 | 0.89 | G6PD (0.40) | IDH1BCHEMGLLALDH1A1KDM4E | |
| SCHEMBL16474705 | 0.86 | PGR (0.42) | BCHEMGLLALDH1A1KDM4EMAPT | |
| SCHEMBL16474693 | 0.85 | PTGS1 (0.44) | ALDH1A1KDM4ESMN1; SMN2MAPK14MAPK11 | |
| SCHEMBL14886523 | 0.79 | IDH1 (0.49) | IDH1MGLLGRM1ALDH1A1KDM4E | |
| SCHEMBL12332875 | 0.79 | IDH1 (0.53) | IDH1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL16474684 | 0.79 | IDH1 (0.49) | IDH1MGLLGRM1MAPT | |
| SCHEMBL4166350 | 0.77 | ALDH1A1 (0.58) | MGLLALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10059769 | 0.76 | CYP1A2 (0.52) | IDH1MGLLGRM1ALDH1A1KDM4E | |
| SCHEMBL10021078 | 0.76 | ALDH1A1 (0.60) | IDH1MGLLALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10059782 | 0.76 | ALDH1A1 (0.49) | IDH1MGLLALDH1A1MAPTHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10233195-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-10233195-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | IDH1 2593/4885BCHE 3921/4885MGLL 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.